Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - Swain, Sandra M.; Miles, David; Kim, Sung-Bae; Im, Young-Hyuck; Im, Seock-Ah; Semiglazov, Vladimir; Ciruelos, Eva; Schneeweiss, Andreas; Loi, Sherene; Monturus, Estefanía; Clark, Emma; Knott, Adam; et al. (The lancet. Oncology, 2020)
Gesehen am 23.04.2020